DexComKPI data tables
DexCom operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash, cash equivalents and marketable securities |
|---|---|
| Q3 2026 | 1.82 |
| Q2 2026 | 1.95 |
| Q1 2026 | 2.42 |
| Q4 2025 | 2 |
| Q3 2025 | 3.32 |
| Q2 2025 | 2.93 |
| Q1 2025 | 2.7 |
| Q4 2024 | 2.58 |
| Q3 2024 | 2.49 |
| Q2 2024 | 3.12 |
| Q1 2024 | 2.9 |
| Q4 2023 | 2.72 |
| Q3 2023 | 3.24 |
| Q2 2023 | 3.64 |
| Q1 2023 | 2.57 |
| Q4 2022 | 2.46 |
| Q3 2022 | 2.37 |
| Q2 2022 | 2.75 |
| Q1 2022 | 2.69 |
| Q4 2021 | 2.73 |
| Q3 2021 | 2.7 |
Source: Dexcom Form 10-Q / Form 10-K condensed balance sheet, SEC XBRL us-gaap:CashAndCashEquivalentsAtCarryingValue plus available-for-sale debt securities (us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest; predecessor us-gaap:AvailableForSaleSecuritiesDebtSecurities). https://data.sec.gov/api/xbrl/companyfacts/CIK0001093557.json. Later filing wins. Period-end STOCK. Window Q3 2021–Q3 2026. Q3 2026 $1.82 billion is cash $961.4 million plus short-term marketable securities $856.5 million on the 30 September 2026 balance sheet (Table A of the earnings release, https://www.sec.gov/Archives/edgar/data/1093557/000109355726000193/dxcm09302026-exhibit991.htm); the release prints $1.82 billion. Q2 2026 $1.95 billion is cash $1,105.0 million plus short-term marketable securities $842.0 million on the 30 June 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm); earnings print $1.95 billion (https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm06302026-exhibit991.htm). Long-term investments and the undrawn revolving credit facility are not cash. Q3 2021 ended 2021-09-30; Q2 2026 ended 2026-06-30; Q3 2026 ended 2026-09-30.
| Period | United States | International |
|---|---|---|
| Q3 2026 | 969.8 | 374.7 |
| Q2 2026 | 933.4 | 375 |
| Q3 2025 | 851.9 | 357.4 |
| Q2 2025 | 841 | 316.1 |
Source: Dexcom Q3 2026 earnings release, Table C. Q3 2026: United States $969.8 million, International $374.7 million; Q3 2025: $851.9 million and $357.4 million (https://www.sec.gov/Archives/edgar/data/1093557/000109355726000193/dxcm09302026-exhibit991.htm). Dexcom Q2 2026 earnings release, Table C. Q2 2026: United States $933.4 million, International $375.0 million. Q2 2025: $841.0 million and $316.1 million. https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Second-Quarter-2026-Financial-Results/default.aspx. SEC: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm06302026-exhibit991.htm.